PreCardix Professional Resources

Recommend PreCardix with Confidence.

Welcome to PreCardix Professional Resources. This section provides important information for health care providers on prescribing PreCardix to patients. Content on this page has been peer-reviewed through third-party health care providers, or internally by our Medical Advisory Board. All content on this site has been reviewed and approved by Hypertension Canada in compliance with their Proud Supporter Program. If you have any additional questions about PreCardix please contact us directly at


Clinical Research

PreCardix is the result of over a decade of blood pressure research and clinical study dedicated to finding an effective, sustainable and proven natural blood pressure solution.

Two clinical studies, Marealis 13TBHM (preliminary clinical trial) and Mare-study (peer-reviewed, double-blind, placebo-controlled, multicentre clinical trial), were conducted on PreCardix between 2012 and 2015 with over two hundred and twenty male and female participants ages 30 – 75. Clinical results show that the bioactive marine peptides in PreCardix have a natural ACE inhibiting effect on the body resulting in a significant blood pressure reduction in over 89% of participants within eight weeks or less.

Highlights Mare-study:

  • 1,200 mg per day of PreCardix® protein hydrolysate was found to have a statistically significant reduction in systolic and diastolic blood pressure on mild to moderate hypertensive subjects
  • Angiotensin II levels were significantly reduced in the treatment group compared to baseline documenting the ACE-inhibitory effect
  • 89% of clinical trial participants experienced a significant blood pressure lowering effect within 8 weeks
  • 43% of clinical trial participants reduced their blood pressure by over 10mmHg in 8 weeks
  • 24% of clinical trial participants reduced their blood pressure by over 15mmHg within 8 weeks



Professional Education



Hypertension Canada